Novel Therapies on the Horizon of Hypertension Management
American Journal of Hypertension · 13.02.2023 · 36 (2) · 73-81
DOI: 10.1093/ajh/hpac111 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift American Journal of Hypertension, online erschienen am 06.10.2022. Verfasst von Olivia Blazek und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, American Heart Association Comprehensive Hypertension Center, University of Chicago Medicine, Chicago, IL 60637, USA. Hauptthemen laut MEDLINE: Hypertension. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 73 Literaturangaben.
Abstract (Originalsprache)
Background
The rates of uncontrolled hypertension, along with downstream cardiovascular outcomes, has been worsening in this country. Despite the plethora of antihypertensive medications on the market, the prevalence of resistant hypertension (RH) is estimated to be 13.7%. Therefore in addition to increased clinical education and focus on lifestyle management of hypertension and medication compliance, new therapies are needed to address this rise in hypertension.
Methods
A systematic review of the available medical literature was performed to identify emerging treatment options for RH.
Results
Six different pharmacologic classes and 2 procedural interventions were identified as being appropriate for review in this paper. The pharmacologic classes to be explored are non-steroidal mineralocorticoid receptor antagonists, aminopeptidase A inhibitors, dual endothelin antagonists, aldosterone synthetase inhibitors, atrial natriuretic peptide inhibitors, and attenuators of hepatic angiotensinogen. Discussion of procedural interventions to lower blood pressure will focus on renal denervation and devices that increase carotid baroreceptor activity.
Conclusions
Promising medication and procedural interventions are being developed and studied to expand our treatment arsenal for patients with uncontrolled essential hypertension and RH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, American Heart Association Comprehensive Hypertension Center, University of Chicago Medicine, Chicago, IL 60637, USA.
ORCID-Profile: George L Bakris
Zitieren
APA
Blazek, O., & Bakris, G. L. (2023). Novel Therapies on the Horizon of Hypertension Management. American Journal of Hypertension, 36(2), 73-81. https://doi.org/10.1093/ajh/hpac111
Vancouver
Blazek O, Bakris GL. Novel Therapies on the Horizon of Hypertension Management. American Journal of Hypertension. 2023;36(2):73-81. doi:10.1093/ajh/hpac111
BibTeX
@article{Blazek2023,
author = {Blazek, Olivia and Bakris, George L},
title = {Novel Therapies on the Horizon of Hypertension Management},
journal = {American Journal of Hypertension},
year = {2023},
volume = {36},
number = {2},
pages = {73--81},
doi = {10.1093/ajh/hpac111}
}
EUVIMED